Coronary Calcium Score: When a CAC Scan Can Change Prevention

A coronary calcium score can change a prevention decision, but it is not a CT scan every adult should add to a check-up. Its best use is narrower: as a tie-breaker for an asymptomatic person whose blood pressure, lipids, smoking, diabetes and estimated risk are known, but whose decision about starting or intensifying cholesterol-lowering therapy remains uncertain.

The result is called a CAC score or Agatston score. Zero usually lowers observed risk over the next several years; 1-99 confirms that calcified plaque is already present; 100 or more often changes the treatment conversation; and 1000 or more identifies extensive disease burden that warrants intensive prevention. No number stands alone. Age, percentile, symptoms, ApoB, Lp(a), blood pressure, smoking, diabetes and family history can all change the interpretation.

Clinical and editorial review: August 5, 2026. We reviewed the same-day search landscape for “coronary calcium score”, “CAC score by age”, “when to get a coronary calcium scan”, “calcio coronario” and “score calcio coronario”. English results are strong on procedure descriptions and generic score tables; Spanish results lean toward imaging explainers and clinic offers. The useful gap is connecting the scan to a real decision and saying when not to order it. This guide is educational and does not replace individual care.

What a coronary artery calcium scan measures

CAC is measured with a noncontrast, ECG-gated cardiac CT. ECG timing reduces motion while the scanner detects calcified plaque in the arteries supplying the heart. Area and density are combined into Agatston units. Image acquisition takes only a few minutes; the full visit is commonly around 10-15 minutes.

With a contemporary protocol, effective radiation is typically about 1 mSv, although scanner, body size and technique matter. There is no iodine injection and the test is noninvasive. Some centers ask patients to avoid caffeine and smoking for a few hours if heart-rate control may affect image quality; follow the imaging center's instructions.

Test	What it shows	Contrast	Main question
CAC score	Amount of calcified coronary plaque	No	Does visible atherosclerosis change risk and prevention?
Coronary CT angiography	Artery lumen, stenosis, calcified and noncalcified plaque	Usually yes	Is anatomical coronary disease or obstruction present?
Exercise stress test	Electrical, hemodynamic and symptom response to workload	No	Does exertion provoke ischemia, arrhythmia or limitation?
Echocardiogram	Heart structure, valves and function	Usually no	Is there a structural or functional abnormality?

CAC does not reliably show noncalcified plaque and does not directly report percent narrowing. A high score does not mean “blocked arteries,” and a zero score does not guarantee plaque-free arteries. It is a marker of calcified atherosclerotic burden and future probability, not an angiogram.

When to get a coronary calcium scan

The 2026 ACC/AHA dyslipidemia guideline places CAC in a sequence: calculate, personalize, reclassify and reassess. For adults aged 30-79 without known cardiovascular disease, PREVENT estimates 10- and 30-year risk. CAC comes later, mainly in men aged at least 40 and women aged at least 45 at borderline or intermediate risk when the decision about lipid-lowering therapy remains uncertain.

In the European 2025 ESC/EAS update, SCORE2 or SCORE2-OP is the starting framework and CAC is a risk modifier for people at moderate risk or around treatment thresholds. Coronary imaging is not recommended as broad population screening. PREVENT and SCORE2 estimate different outcomes in different populations, so their percentages are not interchangeable.

Scenario	Does CAC usually help?	Why
Asymptomatic adult at borderline/intermediate risk who is genuinely unsure about treatment	Often yes	CAC 0 may reclassify risk down; visible plaque can reclassify it up.
High ApoB or Lp(a), premature family history or early menopause with inconclusive calculated risk	Possibly	It asks whether cumulative susceptibility is already visible as calcified atherosclerosis.
Very low risk and no decision would change	Usually little value	Radiation, cost and incidental findings are added without clear benefit.
LDL-C ≥190 mg/dL, familial hypercholesterolemia, known ASCVD or another clear indication for therapy	Not to defer treatment	CAC 0 does not erase cumulative risk or an established indication.
New chest pressure, exertional breathlessness, syncope or a sharp decline in capacity	Not as a standalone test	Symptoms need a diagnostic pathway that may include ECG, troponin, CCTA or other testing.
Prior stent, bypass, heart attack or documented coronary disease	Generally no	Secondary prevention is already indicated and CAC does not monitor response.

CAC score ranges: 0, 1-99, 100, 300 and 1000

The 2026 US guideline describes burden as absent (0), minimal (1-9), mild (10-99), moderate (100-299), severe (300-999) and extensive (1000 or more). The age- and sex-standardized percentile matters alongside the absolute score. CAC 40 in a younger adult may exceed the 75th percentile and represent premature atherosclerosis, while the same value is more common later in life.

Result	Clinical reading	What often changes
0	No calcified plaque detected. Low observed risk for several years, not zero risk.	In selected adults it may support deferring a statin and scheduling reassessment; not when high-risk exceptions apply.
1-99 and <75th percentile	Calcified atherosclerosis is present even if absolute burden is small.	The ACC/AHA guideline considers moderate-intensity treatment and risk-matched goals reasonable.
≥100 or ≥75th percentile	Relevant or premature burden. Observed risk frequently crosses treatment thresholds.	Supports lipid lowering, usually with a statin first, plus tighter control of every major risk factor.
300-999	Severe subclinical atherosclerosis; event rates resemble some secondary-prevention cohorts.	More intensive LDL goals, adherence review and possible combination therapy.
≥1000	Extensive, often multivessel burden and a very-high-risk phenotype.	Prompt clinical review and intensive prevention. It does not automatically mean critical stenosis, catheterization or aspirin.

Effect size: how much observed risk changes

The relationship between CAC and events is one of the most consistent findings in preventive imaging, but most evidence comes from cohorts. MESA enrolled 6,814 adults aged 45-84, from multiple ethnic groups and free of clinical cardiovascular disease, and followed them for a median of 11.1 years. Ten-year ASCVD event rates were 1.3%-5.6% with CAC 0 and 13.1%-25.6% with CAC above 300, depending on age, sex and ethnicity. Each doubling of CAC was associated with a 14% relative increase in risk after adjustment.

The 2026 guideline summarizes MESA this way: CAC 1-100 carried almost four times the coronary-event risk of CAC 0, and CAC 101-300 almost eight times the risk. Those are relative comparisons; absolute probability still depends on the person's baseline context.

At the high end, the CAC Consortium studied 66,636 asymptomatic adults referred for testing over a mean 12.3 years. Among 2,869 people with CAC ≥1000 — mean age 66.3 and 86% men — adjusted cardiovascular mortality was 5.04 times that of CAC 0 (95% CI 3.92-6.48), and all-cause mortality was 2.89 times higher (95% CI 2.53-3.31). Compared with CAC 400-999, cardiovascular mortality was 1.71 times higher.

These effect sizes calibrate severity, but they do not prove that ordering a scan prevents heart attacks. The ESC notes that no randomized trial has yet shown that broad CAC screening and CAC-guided management improve cardiovascular outcomes. More direct behavior evidence shows that revealing CAC can improve treatment uptake, adherence and LDL; evidence that the scan itself reduces events remains indirect.

A CAC score of 0 is not immunity

The “power of zero” means low risk in an appropriate population, not guaranteed absence of disease. Younger plaque may be noncalcified, especially before age 50. CAC also does not diagnose microvascular disease or explain every cause of chest discomfort.

The 2026 guideline allows selected low- or intermediate-risk adults with CAC 0 to defer treatment, but lists major exceptions: familial hypercholesterolemia, LDL-C ≥190 mg/dL, diabetes, current smoking and strong premature family history. Very high Lp(a) or several affected first-degree relatives also deserve caution. Zero today does not erase decades of future exposure.

If treatment is deferred, prevention is not. Blood pressure, tobacco, physical activity, sleep, nutrition, glucose, ApoB and visceral fat still matter. Depending on baseline risk, the guideline suggests reconsidering CAC in roughly 5-7 years at low risk and 3-5 years at intermediate risk.

How CAC fits with PREVENT, ApoB and Lp(a)

Sequence prevents low-value testing. First confirm that the person is asymptomatic and has no known cardiovascular disease. Then establish reliable blood pressure, lipid profile, smoking status, glucose/diabetes, kidney function and medication. In the US, PREVENT estimates 10- and 30-year ASCVD risk from ages 30-79.

Next, personalize. High Lp(a) reveals inherited risk; high ApoB counts atherogenic particles; family history, inflammatory disease, sleep apnea, early menopause and adverse pregnancy outcomes may raise risk. CAC belongs at the end only if uncertainty remains and the result could change a decision.

Consider two 52-year-olds with LDL-C of 145 mg/dL. One has low ApoB, does not smoke, has normal blood pressure, low Lp(a) and CAC 0. The other has high ApoB and Lp(a) plus CAC 180 above the 75th percentile. LDL alone does not tell the same story. CAC does not replace the other inputs; it helps rank them.

What happens after the result

CAC	2026 ACC/AHA framework	Useful next conversation
0	Treatment may be deferred in selected adults without high-risk exceptions.	Address risk factors, set a review date and avoid false reassurance.
1-99 and <p75	Moderate-intensity treatment is reasonable, targeting roughly 30%-49% LDL reduction and LDL-C <100 mg/dL.	Age, percentile, ApoB, tolerance, preferences and lifetime risk.
100-299 or ≥p75	Lipid-lowering therapy is recommended; preferably ≥50% LDL reduction and LDL-C <70 mg/dL.	Statin first-line, with individualized alternatives if insufficient or not tolerated.
300-999	At least 50% LDL reduction and LDL-C <70 mg/dL; <55 mg/dL may be considered in some patients.	Intensity, combination treatment, blood pressure, diabetes, smoking and safe exercise.
≥1000	At least 50% LDL reduction, LDL-C <55 mg/dL and non-HDL-C <85 mg/dL.	Prompt review, multivessel distribution, symptoms, other findings and an integrated plan.

These are US guideline goals, not an automatic prescription for every reader or a literal transfer to another healthcare system. European guidance integrates CAC into global risk and uses its own treatment goals. Drug choice and dose depend on baseline LDL/ApoB, kidney and liver function, interactions, pregnancy potential, adverse effects and patient preference.

A high CAC score also does not order aspirin by itself. In primary prevention, any possible benefit must be balanced against bleeding, age and other factors. Nor does it automatically require a stress test or CCTA in an asymptomatic adult: reflex testing can trigger a cascade without improving outcomes.

Risks, limitations and common mistakes

• Radiation: around 1 mSv with modern protocols, but variable. CT is avoided during pregnancy unless clinically necessary.
• Incidental findings: lung nodules or other findings occur in fewer than 10% in the guideline synthesis, and some require follow-up.
• False reassurance: CAC 0 can miss noncalcified plaque and does not cancel major risk conditions.
• Diagnostic cascades: a high result may lead to imaging, contrast or procedures that do not always add value.
• Not a statin-response marker: therapy may increase calcium density while stabilizing and reducing lipid-rich plaque. Chasing a lower CAC score is the wrong target.
• Measurement variation: scanner, motion and protocol can move small values, so unrelated scans are not directly interchangeable.
• Population limits: reference cohorts do not represent every age, sex, ethnicity and healthcare system equally.

The question before ordering CAC is the one we apply to other longevity biomarkers: what exactly would we do with 0, 80 or 500? If all three answers are the same, the scan probably adds little.

Red flags: do not wait for a calcium score

CAC is mainly intended for asymptomatic risk assessment. New chest pain or pressure, major breathlessness, cold sweat, nausea with pain, pain spreading to the arm, jaw or back, fainting or sudden neurological symptoms require urgent care. A clear recent decline in exercise capacity deserves prompt medical review.

Cardiorespiratory fitness and exercise testing answer functional questions, but neither replaces symptom assessment. In cardiovascular medicine, the right test matters more than the number of tests.

A practical coronary calcium decision table

Question	If yes	If no
Are symptoms or known coronary disease present?	Do not use CAC as a shortcut; follow a diagnostic or secondary-prevention pathway.	Continue to risk estimation.
Do risk and risk enhancers already make the decision clear?	Act on what is known; CT may add little.	Ask whether CAC would resolve uncertainty.
Would the plan change with CAC 0, 1-99 or ≥100?	The test may help after discussing radiation and limits.	Do not order it for curiosity.
Is there a plan to interpret and follow the result?	Name the clinician, goals and review date.	Build continuity before testing.

Sources and certainty

• 2026 ACC/AHA multisociety dyslipidemia guideline: PREVENT, selective CAC use, burden categories and treatment goals.
• JACC 2026 guideline-at-a-glance: calculate-personalize-reclassify framework and clinical messages.
• 2025 ESC/EAS focused update: SCORE2/SCORE2-OP, CAC as a modifier and the case against broad screening.
• MESA 10-year association: 6,814 adults without clinical CVD and absolute event rates across CAC categories.
• CAC Consortium, CAC ≥1000: cardiovascular and all-cause mortality over 12.3 years.
• Statin outcomes after CAC testing: observational gradient of benefit; estimated 10-year NNT 12 for CAC >100 versus 100 for CAC 1-100.
• CAUGHT-CAD randomized trial: CAC-guided protocol, LDL, adherence and plaque progression in premature family history.
• MESA radiation study: effective dose around 1 mSv with contemporary scanners.
• American Heart Association 2026 patient guidance: candidates, procedure and limitations.

Certainty is high that CAC burden predicts events and improves risk reclassification; moderate for using it in a specific shared decision; and insufficient to claim that indiscriminate screening of asymptomatic adults reduces heart attacks or mortality. We will update this guide when outcome trials or major guidelines change.

If your cardiovascular risk seems stuck between two categories, the goal is not another number; it is a resolved decision. Progevita integrates history, blood pressure, ApoB, Lp(a), metabolism, function and imaging only when it can change the plan. Request a clinical orientation and bring previous reports so tests are not repeated without reason.